Rapid Therapeutic Science Laboratories, Inc. (RTSL) Operating Income (2016 - 2023)
Rapid Therapeutic Science Laboratories' Operating Income history spans 7 years, with the latest figure at -$103732.0 for Q2 2023.
- For Q2 2023, Operating Income rose 19.2% year-over-year to -$103732.0; the TTM value through Jun 2023 reached -$547591.0, up 73.17%, while the annual FY2022 figure was -$1.3 million, 41.94% up from the prior year.
- Operating Income for Q2 2023 was -$103732.0 at Rapid Therapeutic Science Laboratories, down from -$98294.0 in the prior quarter.
- Across five years, Operating Income topped out at $27342.0 in Q4 2022 and bottomed at -$789393.0 in Q1 2022.
- The 5-year median for Operating Income is -$496131.0 (2021), against an average of -$363003.0.
- The largest annual shift saw Operating Income plummeted 2266.93% in 2020 before it surged 104.36% in 2022.
- A 5-year view of Operating Income shows it stood at -$22974.0 in 2019, then plummeted by 2124.38% to -$511029.0 in 2020, then decreased by 22.74% to -$627240.0 in 2021, then soared by 104.36% to $27342.0 in 2022, then plummeted by 479.39% to -$103732.0 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Operating Income are -$103732.0 (Q2 2023), -$98294.0 (Q1 2023), and $27342.0 (Q4 2022).